EIKN (NASDAQ:EIKN) Releases Earnings Results

EIKN (NASDAQ:EIKN) posted its quarterly earnings results on Monday. The company reported ($2.46) earnings per share for the quarter, FiscalAI reports.

EIKN Trading Down 0.3%

EIKN traded down $0.03 during midday trading on Monday, reaching $9.93. 566,647 shares of the company’s stock were exchanged, compared to its average volume of 358,441. EIKN has a 1-year low of $7.90 and a 1-year high of $17.40. The company’s 50-day moving average price is $11.30.

Analyst Ratings Changes

A number of equities research analysts have commented on EIKN shares. Wedbush reissued an “underperform” rating and issued a $7.00 target price on shares of EIKN in a report on Tuesday, March 31st. Mizuho started coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 price target for the company. Morgan Stanley started coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “overweight” rating and a $29.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “overweight” rating for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.